← Back to Clinical Trials
Recruiting NCT06062199

NCT06062199 Impact of Implementing the Modified A-DIVA Scale on Successful Access to a Venous Line on the First Attempt

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06062199
Status Recruiting
Phase
Sponsor Centre Jean Perrin
Condition Chronic Disease
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2024-02-27
Primary Completion 2028-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Training in the A-DIVA scale and its failure prediction score

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2024-02-27 with a primary completion date of 2028-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Peripheral venous access (PVA), although commonly used, can be a difficult procedure for patients with precarious venous capital. The difficulty of insertion can lead to multiple attempts, with the consequences of pain, anxiety, delayed management and worsening of the potentially already precarious venous capital. One study assessed the risk of failure according to a score based on venous status criteria. This study first established a link between venous status criteria and the risk of failure. The criteria defined as determinants were used to establish a venous status score. The data were then repeated by analyzing the success rate as a function of the scale score. A clear link between score and risk of failure was established. It seems worthwhile to evaluate the impact of implementing this scale prior to the placement of a peripheral venous line. The hypothesis is that obtaining a score predictive of failure would modify the therapeutic attitude of the registered nurse. They would opt for techniques that would increase their chances of success. This in turn would lead to a reduction in unsuccessful attempts, which generate pain and anxiety for the patient. Preserving venous capital by increasing first-attempt success is both a health issue for the patient and a guarantee of quality of care.

Eligibility Criteria

Inclusion Criteria: * Male or female patient of legal age included in a care program requiring a VVP; * Fluency in French * Patient affiliated to a social security scheme; * Written, signed and dated informed consent. Exclusion Criteria: * As the A-DIVA scale specifies a search for venous access to the upper limb, any patient without an upper limb or with a condition that contraindicates VVP placement in the upper limbs will be excluded; * Patients treated as emergencies; * Patients with a language barrier or known significant cognitive or psychiatric disorders; * Patients under guardianship, curatorship, deprivation of liberty or legal protection; * Pregnant or breast-feeding women.

Contact & Investigator

Central Contact

Judith PASSILDAS JAHANMOHAN, PhD

✉ judith.passildas@clermont.unicancer.fr

📞 +33473278005

Principal Investigator

Lucie MADELAINE

STUDY DIRECTOR

Centre Jean Perrin

Frequently Asked Questions

Who can join the NCT06062199 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06062199 currently recruiting?

Yes, NCT06062199 is actively recruiting participants. Contact the research team at judith.passildas@clermont.unicancer.fr for enrollment information.

Where is the NCT06062199 trial being conducted?

This trial is being conducted at Clermont-Ferrand, France, Clermont-Ferrand, France, Lyon, France.

Who is sponsoring the NCT06062199 clinical trial?

NCT06062199 is sponsored by Centre Jean Perrin. The principal investigator is Lucie MADELAINE at Centre Jean Perrin. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology